NEW YORK (GenomeWeb) – CompanionDx, a high-complexity CLIA-certified laboratory, announced on Monday that it will expand its next-generation sequencing (NGS) offerings with two of Thermo Fisher Scientific cancer assays. 

CompanionDx said it will provide the Oncomine Focus Assay and the Oncomine Comprehensive Assay to clients performing studies across a range of different cancer types. The deal creates new NGS services that could be used in combination with pharmacogenomics to facilitate drug development and clinical research program by drug manufacturers, CompanionDx said. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. 

Sponsored by

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.

Sponsored by

Liquid biopsies are becoming increasingly important for the detection of actionable mutations in cancer due to tumor heterogeneity as well as the practical limitations of invasive tissue biopsies. 

Sponsored by

This webinar will discuss a new approach to amplicon sequencing that addresses the current inefficiencies of the method, such as small designs, primer drop outs, and low uniformity.